Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue

Kura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.77), $0.11 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $20.87 million versus the consensus estimate of $20.16 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• Turning Point Brands (TPB) PT Lowered to $90 at Oppenheimer
• Evercore ISI Reiterates Outperform Rating on Allegion (ALLE)
• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold